Проблемы современной диагностики и лечения дилатационной кардиомиопатии у детей


https://doi.org/10.21508/1027-4065-2018-63-2-7-15

Полный текст:


Аннотация

Представлены данные об  этиологии дилатационной кардиомиопатии у  детей (постмиокардитическая, метаболическая, ассоциированная с  нервно-мышечной патологией, идиопатическая). Освещены генетические аспекты заболевания, описан широкий спектр мутаций в  генах, кодирующих белки различных структур кардиомиоцита (саркомерного комплекса, цитоскелета, Z-дисков, митохондрий), различные варианты наследования. Подчеркнута необходимость ранней диагностики метаболических кардиомиопатий. Представлены критерии неблагоприятного прогноза. Освещены современные подходы к медикаментозному и хирургическому лечению дилатационной кардиомиопатии.

 


Об авторе

И. В. Леонтьева
ОСП «Научно-исследовательский клинический институт педиатрии имени академика Ю.Е. Вельтищева» ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава Российской Федерации, Москва
Россия
д.м.н., проф., главный научный сотрудник отдела детской кардиологии и аритмологии


Список литературы

1. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D. et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiologyand Prevention. Circulation 2006; 113: 1807–1816. DOI 10.1161/ CIRCULATIONAHA.106.174287

2. Lipshultz S.E., Cochran T.R., Briston D.A., Brown S.R., Sambatakos P.J., Miller T.L. et al. Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol 2013; 9: 817–848. DOI: 10.2217/fca.13.66

3. Wilkinson J., Landy D., Colan S, Towbin J., Sleeper L.A., Orav E.J. et al. The Pediatric Cardiomyopathy Registry and Heart Failure: Key Results from the First 15 Years. Heart Fail Clin 2010; 6(4): 401–413. DOI: 10.1016/j.hfc.2010.05.002

4. Schultz M., Hilliard A.A., Cooper L.D., Rihals C. Diagnosis and Treatment of Viral Myocarditis Mayo Clin Proc 2009; 84(11): 1001–1009. DOI: 10.1016/S0025-6196(11)60670-8

5. Caforio A.L., Vinci A., Iliceto S. Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity 2008; 41(6): 462–469. DOI: 10.1080/08916930802031546

6. Kindel S.J., Miller E.M., Gupta R., Cripe L.H., Hinton R.B., Spicer R.L. et al. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail 2012; 18: 396– 403. DOI: 10.1016/j.cardfail.2012.01.017

7. Byers S., Ficicioglu C. Infant with cardiomyopathy: When to suspect inborn errors of metabolism? World J Cardiol 2014; 26; 6(11): 1149–1155. DOI: 10.1080/08916930802031546

8. Леонтьева И.В., Николаева Е.А. Митохондриальные кардиомиопатии. Рос вестн перинатол и педиатр 2016; 61(3): 22–30. DOI: 10.21508/1027-4065-2016-61-3-22-30

9. Steward C.G., Newbury-Ecob R.A., Hastings R., Steward C.G., Newbury-Ecob R.A., Hastings R. et al. Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth. Prenat Diagn 2010; 30: 970–976. DOI: 10.1002/pd.2599

10. Леонтьева И.В., Николаева Е.А. Кардиомиопатии при врожденных нарушениях метаболизма у детей. Рос вестн перинатол и педиатр 2016; 61(2): 17–27. DOI: http: 10.21508/1027-4065-2016-61-2-17-27

11. Wicks E.C., Elliott P.M. Genetics and metabolic cardiomyopathies. Herz 2012; 37: 598–610. DOI: 10.1007/s00059-012-3659-0

12. Diegoli M., Grasso M., Favalli V., Serio A., Gambarin F., Klersy C. et al. Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. J Am Coll Cardiol 2011; 58: 925–34. DOI: 10.1016/j. jacc.2011.01.072

13. Hershberger R., Siegfried M. Update 2011: Clinical and Genetic Issues in Familial Dilated Cardiomyopathy. JACC 2011; 57(16): 1641–1649. DOI: 10.1016/j.jacc.2011.01.015

14. Baars H.F. van der Smagt J.J., Doevendans P.A. Clinical Car-diogenetics. London: Springer, 2011. DOI: 10.1007/978-1-84996-471-5_4.

15. Arbustini E., Narula N., Tavazzi L., Serio A., Grasso M., Fa-valli V. et al. The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol 2014; 64(3): 304–318. DOI: 10.1016/j.jacc.2014.05.027

16. Alexander P.M., Daubeney P.E., Nugent A.W., Lee K.J.,Turner C., Colan S.D. et al. Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy. Circulation 2013; 128: 2039–2046. DOI: 10.1161/ CIRCULATIONAHA.113.002767

17. Alvarez J.A., Orav E.J, Wilkinson J.D., Fleming L.E.,Lee David J., Sleeper L.A. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. Circulation 2011; 124(7): 814–823. DOI: 10.1161 / CIRCULATIONAHA.110.973826

18. Latus H., Gummel K., Klinge K., Moysich A., Khalil M., Mazhari N. et al. Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy. J Cardiovasc Magn Reson 2015; 17: 34. DOI: 10.1186/ s12968-015-0142-0

19. Baba Y., Kubo T., Yamanaka S., Hirota T., Tanioka K., Ya-masaki N. et al. Clinical Significance of High-Sensitivity Cardiac Troponin T in Patients With Dilated Cardiomyopathy. Int Heart J 2015; 56(3): 309–313. DOI: 10.1536/ihj.14-335

20. Auerbach S.R., Richmond M.E., Lamour J.M., Blume E.D., Addonizio L.J., Shaddy R.E. et al. BNP levels predict outcome in pediatric heart failure patients post hoc analysis of the pediatric carvedilol trial. Circ Heart Fail 2010; 3(5): 606–611. DOI: 10.1161/CIRCHEARTFAILURE.109.906875

21. Halliday B.P., Cleland J.G., Goldberger J.J., Prasad S.K. Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future. Circulation 2017; 136(2): 215–231. DOI: 10.1161/CIRCULATIONAHA.116.027

22. Kirk R., Dipchand A.I., Rosenthal D.N., Addonizio L., Burch M., Chrisant M., Dubin A. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. J Heart Lung Transplant 2014; 33(9): 888–909. DOI: 10.1016/j. healun.2014.06.002

23. Kantor P.F., Lougheed J., Dancea A., McGillion M., Bars-bos N., Chan C. et al. Presentation, Diagnosis, and Medical Management of Heart Failure in Children: Canadian Cardiovascular Society Guidelines Canadian Journal of Cardiology 2013;29: 1535–1555. Canad J Cardiol 2013; 29(12): 1535– 1552. DOI: 10.1016/j.cjca.2013.08.008

24. Shaddy R.E., Boucek M.M., Hsu D.T., Boucek R.J., Mahony L., RossR.D. et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298: 1171. DOI: 10.1001/jama.298.10.1171

25. Azeka E., Franchini Ramires J.A., Valler C., Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 40(11): 2034–2038.

26. Reddy S., Fung A., Manlhiot C., Tierney E.S., Chung W.K., Blume E., Kaufman B.D. et al. Adrenergic receptor geno-type influences heart failure severity and β-blocker response in children with dilated cardiomyopathy. Pediatr Res 2015; 77(2): 363–369. DOI: 10.1038

27. Frustaci A., Chimenti C. Immunosuppressive therapy in myocarditis. Circ J 2015; 79(1): 4–7. DOI: 10.1253/circ

28. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cle-land J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. DOI: 10.1093/eurheartj/ehw128

29. Bonnet D., Berger F., Jokinen E., Kantor P.F., Daubeney P.E.F. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol 2017; 70(10): 1262–1272. DOI: 10.1016/j.jacc.2017.07.725

30. Wang N.C., Singh M., Adelstein E.C., Jain S.K., Menden-hall G.S., Shalaby A.A., Voigt A.H., Saba S. New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study. Heart Rhythm 2016; 13(4): 933–942. DOI: 10.1016 /j.hrthm.2015.12.020

31. González -Torrecilla E., Arenal A., Atienza F., Datino T., Bravo L., Ruiz P. et al. Current Indications for Implantable Cardioverter Defibrillators in Non-Ischemic Cardiomyopathies and Channelopathies. Rev Recent Clin Trials 2015; 10(2): 111.

32. Braunwald E.B. The Management of Heart Failure: The Past, the Present, and the Future. Circ Heart Fail 2008; 1: 58–62. DOI: 10.1161 /CIRCHEARTFAILURE.107.752162


Дополнительные файлы

Для цитирования: Леонтьева И.В. Проблемы современной диагностики и лечения дилатационной кардиомиопатии у детей. Российский вестник перинатологии и педиатрии. 2018;63(2):7-15. https://doi.org/10.21508/1027-4065-2018-63-2-7-15

For citation: Leontyeva I.V. Problems of modern diagnostics and treatment of dilated cardiomyopathy in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2018;63(2):7-15. (In Russ.) https://doi.org/10.21508/1027-4065-2018-63-2-7-15

Просмотров: 254

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1027-4065 (Print)
ISSN 2500-2228 (Online)